Cancer Research Technology
Log in Register
Menu

CD47 Knock-out cell line

Invented at Binghamton University

Info

Catalogue Number 157990
Antigen/Gene or Protein Targets CD47
Parental Line B16F10
Host Mouse
Tissue Skin
Disease Keywords melanoma; tumor microenvironment
Model Knock-Out
Relevance CRISPR/Cas9 edited B16F10 cell line designed to help uncover the impact of editing a cell surface protein (CD47), in a tumor microenvironment, and its use as a whole-cell vaccine.
Production Details Cells were cultured in high glucose DMEM and supplemented with 10% v/v Fetal Bovine Serum (FBS)
Research Area Cancer, Cell Signaling & Signal Transduction, Drug Discovery & Development
Positive Control B16F10 parental cells
Notes CRISPR edited B16F10 cells.

Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here.

This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Inducing Tumor Suppressive Microenvironments through Genome Edited CD47 -/- Syngeneic Cell Vaccination


Add a reference

References: 1 entry

Inducing Tumor Suppressive Microenvironments through Genome Edited CD47 -/- Syngeneic Cell Vaccination


Add a reference

Inventor Information

No inventors are currently linked to this reagent.

Add an inventor